由ALK重组和EGFR野生型肺腺癌转化为小细胞肺癌:一个病例报告
Rui Chen1, Yan Jian2, Yuzhen Liu3
1Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Frontiers in oncology
|May 9, 2024
概括
罕见的ALK重组肺腺癌转化为小细胞肺癌,突出了对ALK-TKI的耐药性. 重复活检对于适应晚期肺癌治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 经ALK重组,EGFR野生型肺腺癌 (LUAD) 转化为小细胞肺癌 (SCLC) 是罕见的.
- 这种转变通常与针对性治疗的获得性耐药机制有关.
- 这种现象的早期诊断可能具有挑战性,导致治疗延迟.
更多相关视频
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.3K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
